168 related articles for article (PubMed ID: 26645398)
1. Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma.
Lobo MR; Kukino A; Tran H; Schabel MC; Springer CS; Gillespie GY; Grafe MR; Woltjer RL; Pike MM
PLoS One; 2015; 10(12):e0144488. PubMed ID: 26645398
[TBL] [Abstract][Full Text] [Related]
2. Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse glioma.
Lobo MR; Green SC; Schabel MC; Gillespie GY; Woltjer RL; Pike MM
Neuro Oncol; 2013 Dec; 15(12):1673-83. PubMed ID: 24092859
[TBL] [Abstract][Full Text] [Related]
3. SC68896, a novel small molecule proteasome inhibitor, exerts antiglioma activity in vitro and in vivo.
Roth P; Kissel M; Herrmann C; Eisele G; Leban J; Weller M; Schmidt F
Clin Cancer Res; 2009 Nov; 15(21):6609-18. PubMed ID: 19825946
[TBL] [Abstract][Full Text] [Related]
4. Combined efficacy of cediranib and quinacrine in glioma is enhanced by hypoxia and causally linked to autophagic vacuole accumulation.
Lobo MR; Wang X; Gillespie GY; Woltjer RL; Pike MM
PLoS One; 2014; 9(12):e114110. PubMed ID: 25490024
[TBL] [Abstract][Full Text] [Related]
5. Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
Grossman R; Tyler B; Rudek MA; Kim E; Zadnik P; Khan U; Blakeley JO; Pathak AP; Brem H
Cancer Chemother Pharmacol; 2013 Jul; 72(1):93-100. PubMed ID: 23649683
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of MRI tumor biomarkers to VEGFR inhibitor therapy in an orthotopic mouse glioma model.
Farrar CT; Kamoun WS; Ley CD; Kim YR; Catana C; Kwon SJ; Rosen BR; Jain RK; Sorensen AG
PLoS One; 2011 Mar; 6(3):e17228. PubMed ID: 21390238
[TBL] [Abstract][Full Text] [Related]
7. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
8. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
Kamoun WS; Ley CD; Farrar CT; Duyverman AM; Lahdenranta J; Lacorre DA; Batchelor TT; di Tomaso E; Duda DG; Munn LL; Fukumura D; Sorensen AG; Jain RK
J Clin Oncol; 2009 May; 27(15):2542-52. PubMed ID: 19332720
[TBL] [Abstract][Full Text] [Related]
9. Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas.
Thomsen H; Steffensen E; Larsson EM
Acta Radiol; 2012 Feb; 53(1):95-101. PubMed ID: 22114021
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
[TBL] [Abstract][Full Text] [Related]
11. Depot delivery of dexamethasone and cediranib for the treatment of brain tumor associated edema in an intracranial rat glioma model.
Ong Q; Hochberg FH; Cima MJ
J Control Release; 2015 Nov; 217():183-90. PubMed ID: 26285064
[TBL] [Abstract][Full Text] [Related]
12. Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma.
Ali MM; Janic B; Babajani-Feremi A; Varma NR; Iskander AS; Anagli J; Arbab AS
PLoS One; 2010 Jan; 5(1):e8727. PubMed ID: 20090952
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies.
Kendrew J; Odedra R; Logié A; Taylor PJ; Pearsall S; Ogilvie DJ; Wedge SR; Jürgensmeier JM
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1021-32. PubMed ID: 23355042
[TBL] [Abstract][Full Text] [Related]
14. Cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, inhibits proliferation and enhances therapeutic sensitivity in glioblastoma cells.
Momeny M; Shamsaiegahkani S; Kashani B; Hamzehlou S; Esmaeili F; Yousefi H; Irani S; Mousavi SA; Ghaffari SH
Life Sci; 2021 Dec; 287():120100. PubMed ID: 34715143
[TBL] [Abstract][Full Text] [Related]
15. Assesment of perfusion in glial tumors with arterial spin labeling; comparison with dynamic susceptibility contrast method.
Cebeci H; Aydin O; Ozturk-Isik E; Gumus C; Inecikli F; Bekar A; Kocaeli H; Hakyemez B
Eur J Radiol; 2014 Oct; 83(10):1914-9. PubMed ID: 25087109
[TBL] [Abstract][Full Text] [Related]
16. A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
Towner RA; Ihnat M; Saunders D; Bastian A; Smith N; Pavana RK; Gangjee A
BMC Cancer; 2015 Jul; 15():522. PubMed ID: 26177924
[TBL] [Abstract][Full Text] [Related]
17. [Differentiation between glioma recurrence and radiation-induced brain injuries using perfusion-weighted magnetic resonance imaging].
Wang YL; Liu MY; Wang Y; Xiao HF; Sun L; Zhang J; Ma L
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):416-21. PubMed ID: 23987489
[TBL] [Abstract][Full Text] [Related]
18. A multi-parametric imaging investigation of the response of C6 glioma xenografts to MLN0518 (tandutinib) treatment.
Boult JK; Terkelsen J; Walker-Samuel S; Bradley DP; Robinson SP
PLoS One; 2013; 8(4):e63024. PubMed ID: 23638177
[TBL] [Abstract][Full Text] [Related]
19. [Inhibiting cerebral glioma growth with continuous low-dose chemotherapy and cyclooxygenase-2 inhibitor in nude mice].
Sun JJ; Wang ZY; Liu B; Zhong YF; Du J; Chen YY; Ma CC; Chen XD
Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Jun; 38(3):252-6. PubMed ID: 16778966
[TBL] [Abstract][Full Text] [Related]
20. Adeno-associated virus 2 mediated gene transfer of vascular endothelial growth factor Trap: a new treatment option for glioma.
Zhao S; Zhang Y; Wang L; Yang L; Zou L; Gao F
Cancer Biol Ther; 2019; 20(1):65-72. PubMed ID: 30136881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
